Merck in November said its full trial results showed that molnupiravir lowered the chance of hospitalization or death by about 30% in patie...

The licences are applicable for both active pharmaceutical ingredients (API) and finished product in capsules form. It enables the company ...

Natco Pharma has signed a non-exclusive license agreement with the Medicines Patent Pool (MPP), Switzerland to manufacture and sell Molnupi...

Generic molnupiravir will increase access in India and other low- and middle-income countries (LMICs), while simplifying current supply cha...

Flagging the various health concerns surrounding the Covid anti-viral drug Molnupiravir, ICMR’s Dr Balram Bhargava said that Merck’s corona...

Dr. Reddy’s Molflu will be priced at Rs. 35 per capsule with 10 capsules contained per strip, and the total course of 40 capsules over 5 da...

The recommended dose of molnupiravir is 800 mg twice a day for five days. With companies planning to launch 200 mg capsules, a patient will...

Shares of Strides Pharma were up 2.3 per cent while those of Cipla gained 1.4 per cent. Dr Reddy’s scrip registered a gain of close to a pe...

Molnupiravir is the first COVID-19 drug authorised by the Drugs Controller General of India (DCGI) for the treatment of COVID-19 infection ...

Drug maker Cipla said it will soon make molnupiravir capsules available at all leading pharmacies and Covid treatment centers across the co...

Earlier this year, the Mumbai-based drug major had signed a non-exclusive voluntary licensing agreement with MSD to manufacture and supply ...

Merck's drug, molnupiravir, developed with Ridgeback Biotherapeutics, was shown to reduce hospitalizations and deaths by around 30% in a cl...

The company said the Drugs Controller General of India (DCGI) is currently reviewing clinical data of molnupiravir for the treatment of COV...

The pill was licensed for adults 18 and older who have tested positive for COVID-19 and have at least one risk factor for developing severe...

The ACT-A asks the G20 and other donors for additional funding of $22.8 billion until September 2022 which will be needed to buy and distri...

MSD entered into a voluntary licensing agreement with five Indian drug makers including Sun Pharma, Cipla, Dr. Reddy’s, Emcure and Hetero f...

Molnupiravir was originally developed to treat influenza before US-based Merck initiated research to repurpose drug for use against SARS-Co...